Simcere Pharmaceutical Group Limited Issues Strong Profit Alert for 1H 2026
Key Highlights and Details for Investors
Simcere Pharmaceutical Group Limited (Stock code: 2096) has issued a significant profit alert for the six months ended June 30, 2026 (“1H 2026”), indicating robust growth across both revenue and net profit. This development may have a material impact on the company’s share price, and investors are advised to review the details carefully.
Key Financial Performance Indicators
- Revenue Surge: The Group expects to record revenue between RMB4,550 million and RMB4,610 million for 1H 2026. This represents a strong increase of approximately 26.9% to 28.6% compared to RMB3,585 million for the same period in 2025.
- Net Profit Growth: Profit attributable to equity shareholders is expected to be in the range of RMB810 million to RMB860 million, up by about 34.8% to 43.1% from RMB601 million in 1H 2025.
- Adjusted Profit: On a non-HKFRS adjusted basis, profit attributable to equity shareholders is forecasted at RMB950 million to RMB1,000 million, a substantial increase of 46.5% to 54.2% from the restated and adjusted profit of RMB649 million for 1H 2025.
Drivers of Growth
- The notable increases in both revenue and profit are primarily attributed to strong revenue growth from the Group’s innovative pharmaceutical business and additional income from out-licensing activities.
Accounting Changes and Comparability
- The financial results for 1H 2025 have been restated following the acquisition of Xianwei (Hainan) Biotechnology Co., Ltd. in October 2025, which was treated as a business combination under common control. This restatement ensures comparability between the two periods.
Definition of Adjusted Profit
- Adjusted profit excludes the following: (i) net realized and unrealized gains/losses on financial assets at fair value through profit or loss; (ii) net realized and unrealized gains on associates at fair value through profit or loss; (iii) interest expenses arising from redemption liability; and (iv) related income tax effects. The company believes this measure offers a clearer view of core business performance by eliminating non-recurring or non-operating items.
Important Information for Shareholders
- The figures provided are based on a preliminary assessment of unaudited consolidated management accounts for 1H 2026. Finalized results are subject to confirmation by the Group’s auditors and Audit Committee.
- The official interim results announcement for 1H 2026 is expected in late August 2026.
- Shareholders and potential investors are strongly advised to exercise caution when dealing in the shares of the Company due to the price-sensitive nature of this announcement.
Board Composition
As of the date of the announcement, the Board comprises Mr. Ren Jinsheng as Chairman and executive Director, along with executive Directors Mr. Tang Renhong, Mr. Wan Yushan, and Ms. Wang Xi. The independent non-executive Directors are Mr. Song Ruilin, Mr. Wang Jianguo, Mr. Wang Xinhua, and Mr. Sung Ka Woon.
Potential Share Price Impact
This profit alert reveals significant growth in both top and bottom lines, driven by the expansion of Simcere’s core pharmaceutical business and licensing income. Investors should note that the magnitude of the profit and revenue growth—far exceeding 25% year-on-year—could be highly price sensitive and may materially affect share valuation once the interim results are confirmed. The company’s strategic moves, including M&A activity and focus on innovative pharmaceuticals, are delivering tangible financial results.
Disclaimer: The above article is based on preliminary, unaudited financial information provided by Simcere Pharmaceutical Group Limited and may be subject to adjustments. Investors are encouraged to review the official interim results announcement once published and consult with their financial advisors before making investment decisions.
先聲藥業集團有限公司發佈2026年上半年盈利預告，業績顯著增長
投資者需注意的重點
先聲藥業集團有限公司（股份代號：2096）公佈截至2026年6月30日止六個月（「2026年上半年」）的盈利預告，顯示收入及盈利均有強勁增長。此消息屬於重大事項，或會對公司股價產生顯著影響，投資者應特別留意。
主要財務表現指標
- 收入大幅增長： 預計2026年上半年集團收入約為人民幣45.5億元至46.1億元，較2025年同期的35.85億元，增幅約為26.9%至28.6%。
- 股東應佔溢利增長： 預計2026年上半年歸屬於股東的溢利約為人民幣8.1億元至8.6億元，較2025年同期6.01億元，增幅約為34.8%至43.1%。
- 非香港財務報告準則調整後溢利： 調整後股東應佔溢利預計為人民幣9.5億元至10億元，較2025年同期6.49億元，增幅高達46.5%至54.2%。
增長原因
- 收入和盈利的大幅提升主要來自創新藥業務的收入增加及授權收入的提升。
會計處理及比較性
- 由於2025年10月完成收購「賢為（海南）生物科技有限公司」，該收購按集團內部同一控制下的業務合併處理，2025年上半年財務數據已經重列，確保數據對比具一致性。
調整後溢利定義
- 調整後溢利剔除：（i）按公允價值計入損益的金融資產已實現及未實現收益/虧損；（ii）關聯公司相同項下的收益；（iii）贖回負債的利息開支；及（iv）上述項目的相關所得稅影響。公司認為該指標可更好地反映核心業務的經營表現。
股東需要特別注意
- 是次盈利預告基於集團2026年上半年未經審核的綜合管理賬目初步評估，最終結果尚待核數師及審核委員會確認。
- 2026年上半年的正式業績公告預計於2026年8月下旬發佈。
- 鑒於公告涉及敏感信息，建議股東及潛在投資者在買賣公司股份時務必審慎行事。
董事會組成
截至公告日，董事會由主席兼執行董事任晉生先生領導，執行董事包括唐仁洪、萬宇山及王曦女士，獨立非執行董事為宋瑞林、王建國、王新華及宋家煥先生。
對股價的潛在影響
本次盈利預告反映先聲藥業主營業務及授權收入均有大幅增長，無論收入還是盈利均超過25%的按年增幅，屬高度敏感訊息，或會對公司估值及股價產生重大影響。公司透過創新藥業務及併購策略，已取得實質性業績成果，值得投資者關注。
免責聲明：以上內容根據先聲藥業集團有限公司初步未經審核財務數據編寫，最終業績或有調整。建議投資者待正式業績公告發佈後，並諮詢專業財務顧問後再作投資決定。
